Tonix Pharmaceuticals Holdings CEO Dr. Seth Lederman joined Steve Darling from Proactive to announce that the company has secured exclusive worldwide licensing rights to TNX-4900, a highly selective small-molecule Sigma-1 receptor (S1R) antagonist with demonstrated analgesic activity across multiple preclinical models of neuropathic pain. Lederman explained that Sigma-1 receptor antagonism has attracted growing scientific and clinical interest as a promising new class of non-opioid, non-addictive pain therapies. Tonix has leveraged computer-aided and artificial intelligence–driven drug design approaches to develop this next generation of selective S1R antagonists. TNX-4900 has demonstrated robust and durable pain-relief activity in several validated neuropathic pain models, alongside an encouraging preclinical safety profile. TNX-4900 emerged from a structure-based drug design program led by researchers at Rutgers University, which generated a series of potent and selective triazole-based Sigma-1 receptor antagonists. The compound binds to the human Sigma-1 receptor with nanomolar affinity (Ki = 7.5 nM), exhibits greater than 100-fold selectivity over the Sigma-2 receptor, and shows strong penetration of the blood–brain barrier. In addition, TNX-4900 demonstrates favorable pharmacokinetic characteristics, including attractive absorption, distribution, metabolism, and elimination (ADME) properties and an oral bioavailability of approximately 28%. These attributes support its potential suitability for chronic oral administration in pain indications. In preclinical models of both diabetic neuropathy and chemotherapy-induced neuropathic pain, TNX-4900 produced significant and sustained reductions in pain-related behaviours following both acute and repeated dosing. Importantly, these analgesic effects were observed without evidence of tolerance development or motor impairment, key limitations associated with many existing pain therapies. Tonix plans to advance TNX-4900 through expanded pharmacokinetic, formulation, and safety studies as part of an IND-enabling development program. According to Lederman, the company believes TNX-4900 represents a compelling opportunity to address a large unmet medical need with a differentiated, non-opioid therapeutic option for patients suffering from neuropathic pain. #proactiveinvestors #tonixpharmaceuticalsholdingcorp #nasdaq #tnxp #Biotech #kidneydisease #massachusettsgeneralhospital #massgeneral #VaccineDevelopment #ClinicalTrials #PharmaceuticalNews #MedicalResearch #WHO #GlobalHealth #InfectiousDiseases #SethLederman #ChronicPain #TNX4900 #TONMYA #FibromyalgiaTreatment #NeuropathicPain #PostherpeticNeuralgia #FDAApproval #PharmaNews #ProactiveInvestors